

# Amy E Armstrong

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6120474/publications.pdf>

Version: 2024-02-01

20  
papers

761  
citations

840776

11  
h-index

839539

18  
g-index

20  
all docs

20  
docs citations

20  
times ranked

1514  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor. <i>Nature Genetics</i> , 2017, 49, 1487-1494.	21.4	255
2	Noninvasive Diagnosis of Infection Using Plasma Next-Generation Sequencing: A Single-Center Experience. <i>Open Forum Infectious Diseases</i> , 2019, 6, .	0.9	84
3	Cell-free DNA next-generation sequencing successfully detects infectious pathogens in pediatric oncology and hematopoietic stem cell transplant patients at risk for invasive fungal disease. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27734.	1.5	73
4	Cdkn2a (Arf) loss drives NF1-associated atypical neurofibroma and malignant transformation. <i>Human Molecular Genetics</i> , 2019, 28, 2752-2762.	2.9	54
5	Peptides from cytomegalovirus UL130 and UL131 proteins induce high titer antibodies that block viral entry into mucosal epithelial cells. <i>Vaccine</i> , 2011, 29, 2705-2711.	3.8	53
6	Graft-versus-host disease after solid organ transplantation: A single center experience and review of literature. <i>Annals of Transplantation</i> , 2012, 17, 133-139.	0.9	48
7	Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. <i>Nature Medicine</i> , 2021, 27, 165-173.	30.7	46
8	Entrectinib in children and young adults with solid or primary CNS tumors harboring <i>NTRK</i> , <i>ROS1</i> , or <i>ALK</i> aberrations (STARTRK-NG). <i>Neuro-Oncology</i> , 2022, 24, 1776-1789.	1.2	37
9	A unique subset of low-risk Wilms tumors is characterized by loss of function of TRIM28 (KAP1), a gene critical in early renal development: A Children's Oncology Group study. <i>PLoS ONE</i> , 2018, 13, e0208936.	2.5	35
10	Late Effects in Pediatric High-risk Neuroblastoma Survivors After Intensive Induction Chemotherapy Followed by Myeloablative Consolidation Chemotherapy and Triple Autologous Stem Cell Transplants. <i>Journal of Pediatric Hematology/Oncology</i> , 2018, 40, 31-35.	0.6	26
11	Treatment of neuroblastoma in congenital central hypoventilation syndrome with a <i>PHOX2B</i> polyalanine repeat expansion mutation: New twist on a neurocristopathy syndrome. <i>Pediatric Blood and Cancer</i> , 2015, 62, 2007-2010.	1.5	12
12	The Impact of High-resolution HLA-A, HLA-B, HLA-C, and HLA-DRB1 on Transplant-related Outcomes in Single-unit Umbilical Cord Blood Transplantation in Pediatric Patients. <i>Journal of Pediatric Hematology/Oncology</i> , 2017, 39, 26-32.	0.6	11
13	Irinotecan and temozolomide for treatment of neuroblastoma in a patient with renal failure on hemodialysis. <i>Pediatric Blood and Cancer</i> , 2014, 61, 949-950.	1.5	9
14	Prolonged response to sorafenib in a patient with refractory metastatic osteosarcoma and a somatic <i>PDGFRA</i> D846V mutation. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27493.	1.5	7
15	Neurofibromatosis type 1-related tumours in paediatrics: an evolving treatment landscape. <i>The Lancet Child and Adolescent Health</i> , 2020, 4, 488-490.	5.6	5
16	Early administration of imatinib mesylate reduces plexiform neurofibroma tumor burden with durable results after drug discontinuation in a mouse model of neurofibromatosis type 1. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28372.	1.5	3
17	A Systematic Review of Recent and Ongoing Clinical Trials in Patients With the Neurofibromatoses. <i>Pediatric Neurology</i> , 2022, 134, 1-6.	2.1	2
18	Plexiform neurofibroma: shedding light on the investigational agents in clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 31-40.	4.1	1

#	ARTICLE	IF	CITATIONS
19	LINC-08. Neuro-Oncology tumor board “one-year experience of international collaboration. Neuro-Oncology, 2022, 24, i163-i164.	1.2	0
20	OTHR-18. A pilot study evaluating the access, utilization, and patient satisfaction of basic skin care products among pediatric patients prescribed medications that target the mitogen-activated protein kinase pathway. Neuro-Oncology, 2022, 24, i150-i151.	1.2	0